VCAM1 Specific Neutra™ Antibody Products

Are you struggling with extended drug development timelines or inconsistent antibody validation? Creative Biolabs' VCAM1-specific Neutra™ antibody products feature advanced epitope mapping and affinity maturation to deliver high-specificity antibodies. This streamlines target validation and preclinical efficacy studies.

Introduction to VCAM1

Vascular cell adhesion molecule 1 (VCAM1), a member of the immunoglobulin superfamily, is a transmembrane glycoprotein pivotal in mediating leukocyte-endothelial interactions during inflammation and immune responses. Expressed predominantly on activated endothelial cells, VCAM1 facilitates the adhesion and transmigration of circulating leukocytes by binding to integrin α4β1 (VLA-4) on immune cells. This interaction is central to chronic inflammatory processes, tumor angiogenesis, and autoimmune pathologies.

• Structure

VCAM1 comprises seven extracellular immunoglobulin-like domains, with domains 1 and 4 serving as critical binding sites for VLA-4 integrin. The N-terminal domains (1–3) are essential for high-affinity interactions, while a membrane-proximal mucin-like region enhances ligand accessibility. Structural studies reveal that VCAM1 adopts a flexible conformation, enabling dynamic engagement with integrins under shear stress.

• Related Signaling Pathways

VCAM1 engagement activates intracellular signaling cascades, including NF-κB and MAPK pathways, which amplify endothelial inflammation and promote leukocyte activation. These pathways also crosstalk with cytokine-driven networks (e.g., TNF-α, IL-1β), perpetuating tissue damage in chronic diseases.

Fig.1 VCAM1–mediated leukocyte adhesion and transendothelial migration.¹

• Associated Diseases

VCAM1 overexpression is implicated in atherosclerosis, rheumatoid arthritis, inflammatory bowel disease (IBD), and metastatic cancers. In atherosclerosis, VCAM1 mediates monocyte recruitment to arterial plaques, driving plaque instability. In oncology, VCAM1 fosters tumor angiogenesis and metastatic niche formation by promoting endothelial-immune cell crosstalk.

Fig.2 Role of each VCAM1 in immunological disorders and cancer.¹

Applications of VCAM1 Neutralizing Antibodies

• Targeting Chronic Inflammation

Anti-VCAM1 antibodies inhibit leukocyte infiltration in inflammatory disorders. In preclinical models of rheumatoid arthritis, treatment reduces synovial inflammation and bone erosion by blocking monocyte migration.

• Oncology and Metastasis

By antagonizing VCAM1-mediated tumor angiogenesis, these antibodies suppress metastatic spread. Studies show reduced tumor burden in triple-negative breast cancer models via inhibition of endothelial-tumor cell crosstalk.

• Autoimmune Disease Modulation

In multiple sclerosis, anti-VCAM1 antibodies attenuate blood-brain barrier disruption, lowering CNS immune cell infiltration and demyelination.

• Vascular Injury Repair

Post-ischemic injury, anti-VCAM1 therapy mitigates endothelial dysfunction, improving vascular remodeling in cardiac and cerebral ischemia models.

Our Anti-VCAM1 Antibodies

Our anti-VCAM1 neutralizing antibodies are engineered to disrupt VCAM1-integrin interactions at sub-nanomolar levels. Key features include:

- High Specificity: Targets conformational epitopes in VCAM1 domains 1–2 and 4, preventing VLA-4 binding without cross-reactivity to other adhesion molecules (e.g., ICAM1).

- Functional Validation: Demonstrated efficacy in blocking leukocyte adhesion in flow chamber assays and reducing inflammation in murine models of colitis.

- Theranostic Potential: Compatible with diagnostic imaging (e.g., fluorescence-labeled antibodies for endothelial activation monitoring) and therapeutic applications.

Creative Biolabs' VCAM1-specific Neutra™ antibody products offer superior precision for research and therapeutic development. Engineered to address complex challenges in inflammation, oncology, and autoimmunity, our antibodies are rigorously validated for reproducibility and translational impact.

Contact our team today to explore custom solutions for your project.

REFERENCE

1. Kong, Deok-Hoon, et al. "Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer." International journal of molecular sciences 19.4 (2018): 1057. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms19041057